



Platform for issuing and trading digital assets

www.dexfin.exchange

DEXFIN PROSPECTUS

DEXFIN - Tokenized share (DEXF)

Dexfin, a platform designed to issue and trade tokenized securities will issue its own tokenized security offering (TSO). The issuance will comply with all international laws, related to securities issuance and investors offering.

DIVIDENDS AND BENEFITS

- This type of security token does not constitute ownership (equity) of DEXFIN, but allows token owners to receive 20% of the total revenues earned by the DEXFIN platform.
- The offering is classified as a Revenue Participation Note (RPN), with quarterly payouts to investors.
- Payouts will be made in Bitcoin and EUR, or combination, based on investor choice.
- DEXF token holders will be entitled to exchange 30% of their DEXF token holdings into companies which are going to be tokenized during the upcoming TSO executed by the Dexfin platform.
- DEXF token holders will be entitled to be the first, to invest in the upcoming TSOs executed by the Dexfin platform.

MINIMUM AND CAP ON INVESTMENTS


The minimum investment for retail investors will be €240, with a maximum investment of €5,560,000.

Accredited investors will have a minimum investment requirement of €143,750, with no cap on maximum investment.

DEXF TOKENOMICS

Symbol	DEXF
Hard Cap	5 000 000 EUR
Token Price	0.3 EUR
Type of Token	DXFC - Token
Round Target	3 000 000 EUR
Start of pre-sale	11/4/2019
Green Shoe Option*	500 000 EUR

DEXF Token Allocation



MAIN PLATFORM FEATURES (ACTUAL STATUS)


- Regulatory Compliant Operational Token Issuance Platform for tokenized securities
- DEXF Token Framework - Framework for issuing regulatory compliant tokenized securities
- EURD - eur-pegged stablecoin for blockchain money settlements.
Pegged 1:1 with EUR held in audited accounts.
- Dexfin mobile and web blockchain money transfer app, using our EURD stablecoin
- Research and Development phase of the Dexfin Security Token Exchange

MAIN PLATFORM FEATURES (ASPIRATIONS)

- Develop a tokenized trading system capable of trading tokenized crypto-securities. Enable businesses around the world to overcome traditional finance constraints in order to access the global equity fund of cryptographic securities with the commercial secondary liquidity trading system.
- Dexfin's trading system would solve a huge problem for the crypto community by eliminating liquidity shortages for securities. In the future, truly liquid security tokens can be legally licensed for trading through the Dexfin system and create a new legal approach for the secondary market for trading these securities.
- Dexfin has created a partnership with a robo-advisory firm that is capable of running advanced financial models and creating adaptive dynamic portfolios, benefits that may be available to the token holder in the future.
- A fully functioning Dexfin system could fundamentally disrupt existing capital markets, potentially allowing any public or private company to trade their own tokenized actions - cryptography.
- Continuing innovation that encourages investor confidence in tokenized securities trading.

COMPANY STRATEGY WITH FUNDS RAISED DURING THE SALE

1. The future development of the token business token system itself
2. Strategic acquisitions and investments
3. Development of functional utilities for token owners
4. Increasing technology, infrastructure and staff
5. Legal expenses
6. Lobbying lawmakers and regulators related to Blockchain technology and tokenized securities
7. Global expansion of products and services



DISCLAIMERS

This presentation does not constitute an offer to sell or purchase any product or service of any kind, nor do the contents of the presentation constitute legal, tax or business advice.

Certain statements in this presentation constitute forward-looking statements, and are subject to change. When used in this document, the words “may”, “will”, “should”, “project”, “anticipate”, “believe”, “intend”, “expect”, “continue” and similar expressions or the negatives thereof are generally intended to identify forwardlooking statements. Such forward-looking statements, including the intended actions and performance objectives of DEXF, involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Dexfin to differ materially from any future results, performance or achievements expressed or implied by such forward- looking statements. No representation or warranty is made as to the DEXFIN, future performance or such forward-looking statements, and all such statements speak as of the date hereof, and are subject to change.